FDA advisory panel to review dental amalgam

After receiving several petitions raising concerns about the safety of dental amalgam and the adequacy of the clinical studies used to determine how it should be regulated, the U.S. Food and Drug Administration (FDA) announced today that it will hold an advisory panel meeting December 14-15, 2010, to discuss scientific issues that may affect the regulation of amalgam. The meeting, which is open to the public, will focus particularly on the potential risk to vulnerable populations, such as pregnant women, fetuses, and young children, the agency said.

Click here to read the rest of the article.